171 related articles for article (PubMed ID: 20002663)
1. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy.
Schaeffer EM; Guzzo TJ; Furge KA; Netto G; Westphal M; Dykema K; Yang X; Zhou M; Teh BT; Pavlovich CP
BJU Int; 2010 Jul; 106(1):62-5. PubMed ID: 20002663
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling of renal medullary carcinoma: potential clinical relevance.
Yang XJ; Sugimura J; Tretiakova MS; Furge K; Zagaja G; Sokoloff M; Pins M; Bergan R; Grignon DJ; Stadler WM; Vogelzang NJ; Teh BT
Cancer; 2004 Mar; 100(5):976-85. PubMed ID: 14983493
[TBL] [Abstract][Full Text] [Related]
3. Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival.
Tinari N; Lattanzio R; Natoli C; Cianchetti E; Angelucci D; Ricevuto E; Ficorella C; Marchetti P; Alberti S; Piantelli M; Iacobelli S
Clin Cancer Res; 2006 Mar; 12(5):1501-6. PubMed ID: 16533774
[TBL] [Abstract][Full Text] [Related]
4. Renal medullary carcinoma and ABL gene amplification.
Simpson L; He X; Pins M; Huang X; Campbell SC; Yang XJ; Perlman EJ; Bergan RC
J Urol; 2005 Jun; 173(6):1883-8. PubMed ID: 15879768
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase II alpha expression in testicular germ cell tumors.
Dimov ND; Zynger DL; Luan C; Kozlowski JM; Yang XJ
Urology; 2007 May; 69(5):955-61. PubMed ID: 17482942
[TBL] [Abstract][Full Text] [Related]
6. Renal Medullary Carcinoma and Sickle Cell Trait: A Push for Early Diagnosis and Intervention Report of Two Cases.
Carter SA; Walker AN
J Natl Med Assoc; 2017 Spring; 109(1):63-65. PubMed ID: 28259220
[TBL] [Abstract][Full Text] [Related]
7. Renal medullary carcinoma: the Bronx experience.
Hakimi AA; Koi PT; Milhoua PM; Blitman NM; Li M; Hugec V; Dutcher JP; Ghavamian R
Urology; 2007 Nov; 70(5):878-82. PubMed ID: 18068443
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.
Beckermann KE; Jolly PC; Kim JY; Bordeaux J; Puzanov I; Rathmell WK; Johnson DB
J Immunother Cancer; 2017; 5():1. PubMed ID: 28105368
[TBL] [Abstract][Full Text] [Related]
9. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
Msaouel P; Hong AL; Mullen EA; Atkins MB; Walker CL; Lee CH; Carden MA; Genovese G; Linehan WM; Rao P; Merino MJ; Grodman H; Dome JS; Fernandez CV; Geller JI; Apolo AB; Daw NC; Hodges HC; Moxey-Mims M; Wei D; Bottaro DP; Staehler M; Karam JA; Rathmell WK; Tannir NM
Clin Genitourin Cancer; 2019 Feb; 17(1):1-6. PubMed ID: 30287223
[TBL] [Abstract][Full Text] [Related]
10. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
11. [The medical treatment of renal cancer in adults].
Sculier JP
Rev Med Brux; 1989 May; 10(5):190-6. PubMed ID: 2662317
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
[TBL] [Abstract][Full Text] [Related]
13. Pediatric renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions and clinicopathologic associations.
Altinok G; Kattar MM; Mohamed A; Poulik J; Grignon D; Rabah R
Pediatr Dev Pathol; 2005; 8(2):168-80. PubMed ID: 15747097
[TBL] [Abstract][Full Text] [Related]
14. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome.
Wood CG
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):697s-702s. PubMed ID: 17255296
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
16. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
[TBL] [Abstract][Full Text] [Related]
17. Cytology of metastatic renal medullary carcinoma in pleural effusion: a study of two cases.
Ellis CL; Burroughs F; Michael CW; Li QK
Diagn Cytopathol; 2009 Nov; 37(11):843-8. PubMed ID: 19526572
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase II alpha status in renal medullary carcinoma: immuno-expression and gene copy alterations of a potential target of therapy.
Albadine R; Wang W; Brownlee NA; Toubaji A; Billis A; Argani P; Epstein JI; Garvin AJ; Cousi R; Schaeffer EM; Pavlovich C; Netto GJ
J Urol; 2009 Aug; 182(2):735-40. PubMed ID: 19539329
[TBL] [Abstract][Full Text] [Related]
20. [New entities in pathological classification and new therapeutic options in renal cell carcinoma].
Bay JO; Penault-Llorca F; Ravaud A; Chevreau C; Négrier S; Escudier B
Bull Cancer; 2006 Jan; 93(1):91-100. PubMed ID: 16455511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
